Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03593681 · ClinicalTrials.gov registry record
Compare Fallopian Tube Cells Collected by Cytuity With Removed Ovarian/Tubal Tissue to Determine Presence of Malignancy
A clinical trial, sponsored by Boston Scientific Corporation.
- Completed
- Registry status
- 150
- Enrollment target
NCT03593681: Completed study, sponsored by Boston Scientific Corporation.
NCT03593681 is a clinical trial that has completed, run by Boston Scientific Corporation. The registered enrollment target is 150 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03593681 has completed, sponsored by Boston Scientific Corporation.
- COMPLETED
- Registry status
- 150 participants
- Enrollment target
Study Summary
Prospective, multi-center, non-randomized study to assess the ability of the Cytuity device to collect cell samples from the fallopian tube that can be evaluated for the presence or absence of malignancy.
Primary Outcome
Evaluate the sensitivity and specificity of the cytological samples collected from the fallopian tube in determining the presence or absence of malignancy for fallopian tube involvement as compared to the surgical histology results. Fallopian tube involvement was defined as: 1. Malignant cells that originated in the fallopian tube, detected by the surgical histology results from the fallopian tube. 2. Malignant cells that have migrated to the fallopian tube, detected by surgical histology result
Interventions
- DEVICE Hysteroscopic cell sampling of the fallopian tube
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2018-08-27 |
| Est. Completion | 2020-02-14 |
What the finished NCT03593681 record still lists
NCT03593681 is an observational study that tracks outcomes without assigning an intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Hysteroscopic cell sampling of the fallopian tube is the first listed.
NCT03593681 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03593681 about?
NCT03593681 is a clinical study titled "Compare Fallopian Tube Cells Collected by Cytuity With Removed Ovarian/Tubal Tissue to Determine Presence of Malignancy". Prospective, multi-center, non-randomized study to assess the ability of the Cytuity device to collect cell samples from the fallopian tube that can be evaluated for the presence or absence of malignancy.
What is the current status of trial NCT03593681?
This trial is currently completed. The enrollment target is 150 participants. The study started on 2018-08-27. Estimated completion is 2020-02-14.
What interventions are being tested in trial NCT03593681?
The interventions under investigation include: Hysteroscopic cell sampling of the fallopian tube (DEVICE).
Who is sponsoring clinical trial NCT03593681?
This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI